ResearcherAustralian National UniversityActive in the last 2 years
Desmond Yip
Matched on ORCID iD 0000-0002-2806-2401; OpenAlex author ID A5012142507. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 2, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 15
2015: 2 papers · 2016: none · 2017: 1 paper · 2018: 2 papers · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper
Papers 8
- Neoadjuvant Chemotherapy With Chemoradiotherapy for Patients With Borderline Resectable or Locally Advanced Pancreatic Ductal Adenocarcinoma-Retrospective Revi… First author DOI 10.1111/ajco.14166↗
- Chemotherapy and radiotherapy for advanced pancreatic cancer. Co-author DOI 10.1002/14651858.cd011044.pub3↗
- Neoadjuvant Chemotherapy in Pancreatic Cancer. First author DOI 10.1001/jamasurg.2020.6276↗
- Chemotherapy and radiotherapy for advanced pancreatic cancer. Last author DOI 10.1002/14651858.cd011044.pub2↗
- Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future. Co-author DOI 10.1111/imj.13810↗
- Advanced pancreatic ductal adenocarcinoma - Complexities of treatment and emerging therapeutic options. Last author DOI 10.3748/wjg.v23.i13.2276↗
- Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials. Last author DOI 10.1016/j.critrevonc.2015.07.007↗
- New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma. Co-author DOI 10.1200/jco.2013.51.5783↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Adnan M. Nagrial · 5 shared papers, 2015–2024 · strength 0.53
- Paper Chemotherapy and radiotherapy for advanced pancreatic cancer. DOI 10.1002/14651858.cd011044.pub3↗
- Paper Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future. DOI 10.1111/imj.13810↗
- Paper Chemotherapy and radiotherapy for advanced pancreatic cancer. DOI 10.1002/14651858.cd011044.pub2↗
- Ankit Jain · 2 shared papers, 2021–2025 · strength 0.52
- Sivakumar Gananadha · 2 shared papers, 2021–2025 · strength 0.52
- Venessa T. Chin · 4 shared papers, 2015–2024 · strength 0.49
- Paper Chemotherapy and radiotherapy for advanced pancreatic cancer. DOI 10.1002/14651858.cd011044.pub3↗
- Paper Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future. DOI 10.1111/imj.13810↗
- Paper Chemotherapy and radiotherapy for advanced pancreatic cancer. DOI 10.1002/14651858.cd011044.pub2↗
- Lorraine A. Chantrill · 3 shared papers, 2018–2024 · strength 0.43
- Paper Chemotherapy and radiotherapy for advanced pancreatic cancer. DOI 10.1002/14651858.cd011044.pub3↗
- Paper Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future. DOI 10.1111/imj.13810↗
- Paper Chemotherapy and radiotherapy for advanced pancreatic cancer. DOI 10.1002/14651858.cd011044.pub2↗
- Avtaj Nerwal · 1 shared paper, 2025 · strength 0.30
- Belinda Lee · 1 shared paper, 2025 · strength 0.30
- Lucy Haggstrom · 1 shared paper, 2024 · strength 0.24
- Andrew Victor Biankin · 3 shared papers, 2015–2018 · strength 0.19
- Paper Chemotherapy and radiotherapy for advanced pancreatic cancer. DOI 10.1002/14651858.cd011044.pub2↗
- Paper Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials. DOI 10.1016/j.critrevonc.2015.07.007↗
- Paper New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma. DOI 10.1200/jco.2013.51.5783↗
- Adrian M. J. Pokorny · 1 shared paper, 2018 · strength 0.11
- Chandra Sai Diwakarla · 1 shared paper, 2017 · strength 0.10
- Marina Pajic · 1 shared paper, 2015 · strength 0.06
- Georgina Venetia Long · 1 shared paper, 2015 · strength 0.05
- Matteo Salvatore Carlino · 1 shared paper, 2015 · strength 0.05
- Sean Michael Grimmond · 1 shared paper, 2015 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.